In vivo monitoring of drugs using radiotracer techniques

Advanced Drug Delivery Reviews

Volumn 41, Issue 1, 2000, Pages 21-39

  Saleem, Azeem ^a   Aboagye, Eric O ^a   Price, Patricia M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

5 Fluorouracil; Drug receptor interaction; Drug resistance; PET; Pharmacodynamics; Pharmacokinetics; SPECT

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DRUG INTERACTIONS; GENES; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT);

CONTROLLED DRUG DELIVERY;

ACETIC ACID; AMMONIA; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBON MONOXIDE; CARMUSTINE; CISPLATIN; DRUG RECEPTOR; FLUCONAZOLE; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE DERIVATIVE; METHIONINE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE; NEUROLEPTIC AGENT; QUETIAPINE; RACLOPRIDE; SPARFOSIC ACID; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE; TRACER; TYROSINE; UNINDEXED DRUG; WATER; ZIPRASIDONE;

DOSE CALCULATION; DRUG DESIGN; DRUG LABELING; DRUG MECHANISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TUMOR LEVEL; HUMAN; HYPOXIA; IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE PERFUSION; TREATMENT OUTCOME; TUMOR;

DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FLUCONAZOLE; FLUOROURACIL; HUMANS; MODELS, BIOLOGICAL; RADIONUCLIDE IMAGING; RECEPTORS, CELL SURFACE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034005438     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00054-X     Document Type: Article

References (136)

1. Laurence D.R., Bennett P.N., Brown M.J. General pharmacology. Clinical Pharmacology. 8th Edition:1997;77-120 Churchill Livingstone, London.
2. Ranson M.R., Scarffe J.H. Population and Bayesian pharmacokinetics in oncology. Clin. Oncol. 6:1994;254-260.
3. Cho Z.H., Chan J.K., Ericksson L., Singh M., Graham S., MacDonald N.S., Yano Y. Positron ranges obtained from biomedically important positron-emitting radionuclides. J. Nucl. Med. 16:1975;1174-1176.
4. 11C]CGP 12177) as a preferred radioligand for beta-adrenergic receptors. Int. J. Rad. Appl. Instrum. A. 42:1991;621-628.
5. Mintun M.A., Welch M.J., Siegel B.A., Mathias C.J., Brodack J.W., McGuire A.H., Katzenellenbogen J.A. Breast cancer: PET imaging of estrogen receptors. Radiology. 169:1988;45-48.
6. Strauss L.G., Conti P.S. The applications of PET in clinical oncology. J. Nucl. Med. 32:1991;623-648. discussion 49-50.
7. 18F-dopa PET study [see comments]. Neurology. 42:1992;1554-1560.
8. Huang S.C., Phelps M.E. Principles of tracer kinetic modeling in positron tomography and autoradiography. Phelps M.E., Mazziota J.C., Schelbert H.R. Positron Emission Tomography and Autoradiography: Principles and applications for the brain and heart. 1986;287-346 Raven Press, New York.
9. Cunningham V.J., Jones T. Spectral analysis of dynamic PET studies. J. Cereb. Blood Flow Metab. 13:1993;15-23.
10. Meikle S.R., Matthews J.C., Brock C.S., Wells P., Harte R.J.A., Cunningham V.J., Jones T., Price P. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother. Pharmacol. 42:1998;183-193.
11. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
12. Lavin P., Mittleman A., Douglass H. Jr., Engstrom P., Klaassen D. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report. Cancer. 46:1980;1536-1543.
13. Richards F., Case L.D., White D.R., Muss H.B., Spurr C.L., Jackson D.V., Cooper M.R., Zekan P., Cruz J., Stuart J.J., et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol. 4:1986;565-570.
14. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. [see comments. J. Clin. Oncol. 10:1992;896-903.
15. 18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res. 37:1977;2306-2308.
16. 18F-5-fluorouracil. Int. J. Nucl. Med. Biol. 9:1982;25-35.
17. Young D., Vine E., Ghanbarpour A., Shani J., Siemsen J.K., Wolf W. Metabolic and distribution studies with radiolabeled 5-fluorouracil. Nuklearmedizin. 21:(1):1982;1-7.
18. 18F-5-fluorouracil. Int. J. Appl. Radiat. Isot. 30:1979;401-405.
19. 18F]Fluorouracil using HPLC and a study of its metabolic profile in rats. J. Label Compd. Radiopharm. 32:1993;521-522.
20. Dimitrakopoulou A., Strauss L.G., Clorius J.H., Ostertag H., Schlag P., Heim M., Oberdorfer F., Helus F., Haberkorn U., van Kaick G. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 34:1993;1075-1081.
21. 18F]uracil positron emission tomography (PET). Eur J Cancer. 12:1993;1682-1686.
22. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 57:1997;3415-3423.
23. Dimitrakopoulou-Strauss A., Strauss L.G., Schlag P., Hohenberger P., Irngartinger G., Oberdofer F., Doll J., van Kaick G. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18- labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J. Nucl. Med. 39:1998;465-473.
24. Dimitrakopoulou-Strauss A., Strauss L.G., Schlag P., Hohenberger P., Mohler M., Oberdorfer F., van Kaick G. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J. Nucl. Med. 39:1998;1197-1202.
25. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer. 83:1998;245-253.
26. 18F]fluorouracil. J. Nucl. Med. 39:1998;1370-1376.
27. Kissel J., Port R.E., Zaers J., Bellemann M.E., Strauss L.G., Haberkorn U., Brix G. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach [In Process Citation]. Med. Phys. 26:1999;609-615.
28. Harte R.J., Matthews J.C., O’Reilly S.M., Tilsley D.W., Osman S., Brown G., Luthra S.J., Brady F., Jones T., Price P.M. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J. Clin. Oncol. 17:1999;1580-1588.
29. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 8:1990;1868-1873.
30. Presant C.A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blayney D., Brechner R.R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response [see comments]. Lancet. 343:1994;1184-1187.
31. Richardson K. The discovery and profile of fluconazole. J. Chemother. 2:1990;51-54.
32. Van den Bossche H., Willemsens G., Cools W., Marichal P., Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem. Soc. Trans. 11:1983;665-667.
33. Van Cauteren H., Lampo A., Vandenberghe J., Vanparys P., Coussement W., De Coster R., Marsboom R. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses. 32 S1:1989;60-66.
34. Humphrey M.J., Jevons S., Tarbit M.H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents. Chemother. 28:1985;648-653.
35. 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 37:1993;1270-1277.
36. Hughes C.E., Bennett R.L., Tuna I.C., Beggs W.H. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob. Agents Chemother. 32:1988;209-212.
37. Ragosta M., Beller G.A. The noninvasive assessment of myocardial viability. Clin. Cardiol. 16:1993;531-538.
38. Schelbert H.R., Henze E., Phelps M.E., Kuhl D.E. Assessment of regional myocardial ischemia by positron-emission computed tomography. Am. Heart J. 103:1982;588-597.
39. Kumar A., Schapiro M.B., Grady C., Haxby J.V., Wagner E., Salerno J.A., Friedland R.P., Rapoport S.I. High-resolution PET studies in Alzheimer’s disease. Neuropsychopharmacology. 4:1991;35-46.
40. Kushner M., Fieschi C., Alavi A., Silver F., Chawluk J., Reivich M. Local cerebral metabolic changes in acute ischemic strokes. Gerontology. 33:1987;265-267.
41. Warburg, O., (1931) The metabolism of Tumours. In: Richard Smith, New York, pp. 129-169.
42. Warburg O., Wind F., Neglers E. On the metabolism of tumours in the body. Warburg O. Metabolism of Tumours. 1930;254-270 Arnold Constable, London.
43. Gallagher B.M., Fowler J.S., Gutterson N.I., MacGregor R.R., Wan C.N., Wolf A.P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J. Nucl. Med. 19:1978;1154-1161.
44. Weber G. Enzymology of cancer cells (first of two parts). New Engl. J. Med. 296:1977;486-492.
45. Weber G. Enzymology of cancer cells (second of two parts). New Engl. J. Med. 296:1977;541-551.
46. Brock C.S., Meikle S.R., Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [see comments]. Eur. J. Nucl. Med. 24:1997;691-705.
47. Haberkorn U., Strauss L.G., Dimitrakopoulou A., Seiffert E., Oberdorfer F., Ziegler S., Reisser C., Doll J., Helus F., van Kaick G. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med. 34:1993;12-17.
48. Holthoff V.A., Herholz K., Berthold F., Widemann B., Schroder R., Neubauer I., Heiss W.D. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 72:1993;1394-1403.
49. Okada J., Oonishi H., Yoshikawa K., Itami J., Uno K., Imaseki K., Arimizu N. FDG-PET for predicting the prognosis of malignant lymphoma. Ann. Nucl. Med. 8:1994;187-191.
50. Okazumi S., Isono K., Enomoto K., Kikuchi T., Ozaki M., Yamamoto H., Hayashi H., Asano T., Ryu M. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment [see comments]. J. Nucl. Med. 33:1992;333-339.
51. Jansson T., Westlin J.E., Ahlstrom H., Lilja A., Langstrom B., Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J. Clin. Oncol. 13:1995;1470-1477.
52. Findlay M., Young H., Cunningham D., Iveson A., Cronin B., Hickish T., Pratt B., Husband J., Flower M., Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J. Clin. Oncol. 14:1996;700-7008.
53. Ogawa T., Uemura K., Shishido F., Yamaguchi T., Murakami M., Inugami A., Kanno I., Sasaki H., Kato T., Hirata K., et al. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr. 12:1988;290-297.
54. 11C-methyl-L-methionine positron emission tomography in patients with primary cerebral malignant lymphoma. Neuroradiology. 34:1992;517-519.
55. 11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br. J. Urol. 74:1994;767-774.
56. Huovinen R., Leskinen Kallio S., Nagren K., Lehikoinen P., Ruotsalinen U., Teras M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br. J. Cancer. 67:1993;787-791.
57. 11C]methionine and 18F- fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur. J. Nucl. Med. 18:1991;453-460.
58. Reinhardt M.J., Kubota K., Yamada S., Iwata R., Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J. Nucl. Med. 38:1997;280-287.
59. Sato K., Kameyama M., Ishiwata K., Katakura R., Yoshimoto T. Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers. J. Neurooncol. 14:1992;81-89.
60. Kety S.S. Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med. Res. 8:1960;228-236.
61. 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int. J. Rad. Appl. Instrum. A. 37:1986;1039-1043.
62. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231:1986;258-261.
63. Wagner H.N. Jr., Burns H.D., Dannals R.F., Wong D.F., Langstrom B., Duelfer T., Frost J.J., Ravert H.T., Links J.M., Rosenbloom S.B., Lukas S.E., Kramer A.V., Kuhar M.J. Imaging dopamine receptors in the human brain by positron tomography. Science. 221:1983;1264-1266.
64. 18F-labeled setoperone. J. Neurochem. 54:1990;1744-1754.
65. Charbonneau P., Syrota A., Crouzel C., Valois J.M., Prenant C., Crouzel M. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation. 73:1986;476-483.
66. Maziere M., Hantraye P., Kaijima M., Dodd R., Guibert B., Prenant C., Sastre J., Crouzel M., Comar D., Naquet R. Visualization by positron emission tomography of the apparent regional heterogeneity of central type benzodiazepine receptors in the brain of living baboons. Life Sci. 36:1985;1609-1616.
67. 11C]diprenorphine in normal volunteers. J. Neurosci. Methods. 23:1988;121-129.
68. Frost J.J., Mayberg H.S., Fisher R.S., Douglass K.H., Dannals R.F., Links J.M., Wilson A.A., Ravert H.T., Rosenbaum A.E., Snyder S.H., Wagner H.N. Jr. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann. Neurol. 23:1988;231-237.
69. Syrota A. In vivo investigation of myocardial perfusion, metabolism and receptors by positron emission tomography. Int. J. Microcirc. Clin. Exp. 8:1989;411-422.
70. Syrota A., Paillotin G., Davy J.M., Aumont M.C. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci. 35:1984;937-945.
71. VanBrocklin H.F., Liu A., Welch M.J., O’Neil J.P., Katzenellenbogen J.A. The synthesis of 7-alpha-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids. 59:1994;34-45.
72. Katzenellenbogen J.A., Welch M.J., Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 17:1997;1573-1676.
73. de Groot T.J., Verhagen A., Elsinga P.H., Vaalburg W. Synthesis of [18F]fluoro-labeled progestins for PET. Int. J. Rad. Appl. Instrum. [A]. 42:1991;471-474.
74. Liu A., Carlson K.E., Katzenellenbogen J.A. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J. Med. Chem. 35:1992;2113-2129.
75. Bonasera T.A., O’Neil J.P., Xu M., Dobkin J.A., Cutler P.D., Lich L.L., Choe Y.S., Katzenellenbogen J.A., Welch M.J. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J. Nucl. Med. 37:1996;1009-1015.
76. 11C]N, N-dimethylphenylethylamine in mice and humans: potential for measurement of brain MAO-B activity. J. Nucl. Med. 28:1987;1006-1011.
77. Vollenweider-Zerargui L., Barrelet L., Wong Y., Lemarchand-Beraud T., Gomez F. The predictive value of estrogen and progesterone receptors’ concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer. 57:1986;1171-1180.
78. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J. Nucl. Med. 32:1991;1526-1531.
79. Dehdashti F., Flanagan F.L., Mortimer J.E., Katzenellenbogen J.A., Welch M.J., Siegel B.A. Positron emission tomographic assessment of metabolic flare to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 26:1999;51-56.
80. Campbell F.C., Blamey R.W., Elston C.W., Morris A.H., Nicholson R.I., Griffiths K., Haybittle J.L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 2:1981;1317-1319.
81. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin. Cancer Res. 2:1996;933-939.
82. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
83. Seeman P., Lee T., Chsu-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
84. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45:1988;71-76.
85. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 33:1993;227-235.
86. Wiesel F.A., Farde L., Nordstrom A.L., Sedvall G. Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1990;759-767.
87. Farde L., Wiesel F.A., Nordstrom A.-L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 99:1989;28-31.
88. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
89. 11C-raclopride. Psychopharmacology. 112:1993;308-314.
90. Gefvert O., Bergstrom M., Langstrom B., Lundberg T., Lindstrom L., Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl). 135:1998;119-126.
91. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre- clinical development and clinical trials. Cancer Treat. Rev. 23:1997;35-61.
92. 11C -methyl]methylisocyanate and application of microwave heating to labelling the novel anticancer agent Temozolomide. J. Label Compd. Radiopharm. 35:1994;100-103.
93. Bellamy W.T., Dalton W.S., Dorr R.T. The clinical relevance of multidrug resistance. Cancer Invest. 8:1990;547-562.
94. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
95. Zijlstra J.G., de Vries E.G., Mulder N.H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47:1987;1780-1784.
96. Germann U.A., Pastan I., Gottesman M.M. P-glycoproteins: mediators of multidrug resistance. Semin. Cell Biol. 4:1993;63-76.
97. Hendrick A.M., Harris A.L., Cantwell B.M. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann. Oncol. 2:1991;71-72.
98. Rodenburg C.J., Nooter K., Herweijer H., Seynaeve C., Oosterom R., Stoter G., Verweij J. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann. Oncol. 2:1991;305-306.
99. Wood L., Palmer M., Hewitt J., Urtasun R., Bruera E., Rapp E., Thaell J.F. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br. J. Cancer. 77:1998;627-631.
100. Bailly J.D., Muller C., Jaffrezou J.P., Demur C., Gassar G., Bordier C., Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 9:1995;799-807.
101. Kostakoglu L., Elahi N., Kiratli P., Ruacan S., Sayek I., Baltali E., Sungur A., Hayran M., Bekdik C.F. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J. Nucl. Med. 38:1997;1003-1008.
102. Vecchio S.D., Ciarmiello A., Potena M.I., Carriero M.V., Mainolfi C., Botti G., Thomas R., Cerra M., D’Aiuto G., Tsuruo T., Salvatore M. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients [see comments]. Eur. J. Nucl. Med. 24:1997;150-159.
103. Ciarmiello A., Del Vecchio S., Silvestro P., Potena M.I., Carriero M.V., Thomas R., Botti G., D’Aiuto G., Salvatore M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J. Clin. Oncol. 16:1998;1677-1683.
104. Chen C.C., Meadows B., Regis J., Kalafsky G., Fojo T., Carrasquillo J.A., Bates S.E. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res. 3:1997;545-552.
105. Luker G.D., Fracasso P.M., Dobkin J., Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J. Nucl. Med. 38:1997;369-372.
106. Elsinga P.H., Franssen E.J., Hendrikse N.H., Fluks L., Weemaes A.M., van der Graaf W.T., de Vries E.G., Visser G.M. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J. Nucl. Med. 37:1996;1571-1575.
107. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., Vaalburg W., Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 59:1999;2411-2416.
108. Casciari J.J., Graham M.M., Rasey J.S. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med. Phys. 22:1995;1127-1139.
109. Koh W.J., Bergman K.S., Rasey J.S., Peterson L.M., Evans M.L., Graham M.M., Grierson J.R., Lindsley K.L., Lewellen T.K., Krohn K.A., Griffin T.W. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;391-398.
110. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;417-428.
111. Aboagye E.O., Kelson A.B., Tracy M., Workman P. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des. 13:1998;703-730.
112. Blakey D.C., Burke P.J., Davies D.H., Dowell R.I., Melton R.G., Springer C.J., Wright A.F. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Biochem. Soc. Trans. 23:1995;1047-1050.
113. Blakey D.C., Burke P.J., Davies D.H., Dowell R.I., East S.J., Eckersley K.P., Fitton J.E., McDaid J., Melton R.G., Niculescu Duvaz I.A., Pinder P.E., Sharma S.K., Wright A.F., Springer C.J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res. 56:1996;3287-3292.
114. 11C] ethylene; a reagent for introducing the halooethyl group into antibody directed enzyme prodrugs (ADEPT). J. Label Compd. Radiopharm. 37:1995;95-97.
115. Tjuvajev J.G., Avril N., Oku T., Sasajima T., Miyagawa T., Joshi R., Safer M., Beattie B., DiResta G., Daghighian F., Augensen F., Koutcher J., Zweit J., Humm J., Larson S.M., Finn R., Blasberg R. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58:1998;4333-4341.
116. Inoue T., Kim E.E., Wallace S., Yang D.J., Wong F.C., Bassa P., Buzdar A.U., Podoloff D.A. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin. Imaging. 21:1997;332-336.
117. 11C]BCNU evaluated by PET. J. Nucl. Med. 27:1986;775-780.
118. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J. Neurooncol. 10:1991;47-55.
119. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28:1987;1844-1852.
120. Front D., Israel O., Iosilevsky G., Even Sapir E., Frenkel A., Kolodny G.M., Feinsod M. SPECT quantitation of cobalt-57 bleomycin delivery to human brain tumors. J. Nucl. Med. 29:1988;187-194.
121. Front D., Israel O., Even Sapir E., Iosilevsky G., Frenkel A., Ben Haim S., Ber R., Robinson E., Kolodny G.M. The concentration of bleomycin labeled with Co-57 in primary and metastatic tumors. Cancer. 64:1989;988-993.
122. Front D., Even Sapir E., Israel O., Iosilevsky G., Frenkel A., Milstein D., Epelbaum R., Robinson E., Kolodny G.M. In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. Cancer. 67:1991;2477-2483.
123. Even Sapir E., Bettman L., Iosilevsky G., Milshtein D., Frenkel A., Kolodny G.M., Ben Haim S., Israel O., Front D. SPECT quantitation of cobalt-57-bleomycin to predict treatment response and outcome of patients with lung cancer [see comments]. J. Nucl. Med. 35:1994;1129-1133.
124. 11C]N- [2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res. 57:1997;2172-2180.
125. Harte R.J.A., Matthews J.C., Flavin A., Brock C.S., Osman S., Luthra S.K., Brown G., Brady F., Jones T., Bleehan N., Price P. Pre phase I tracer kinetic studies in humans can contribute to new drug evaluation (Meeting abstract). Proceedings 9th NCI/EORTC Symposium on New Drugs in Cancer Therapy:1996;A48.
126. Brock C.S., Matthews J.C., Brown G., Luthra S.K., Brady F., Newlands E.S., Price P. The kinetic behavior of temozolomide in man (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 15:1996;A 1502.
127. Brock C.S., Matthews J.C., Brown G., Osman S., Luthra S.K., Brady F., Newlands E.S., Price P. Temozolomide uptake in human astrocytomas demonstrated in vivo (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16:1997;A 812.
128. 2O, [15O]CO, and positron emission tomography. Diabetes. 46:1997;2017-2021.
129. Chan S.Y., Brunken R.C., Czernin J., Porenta G., Kuhle W., Krivokapich J., Phelps M.E., Schelbert H.R. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J. Am. Coll. Cardiol. 20:1992;979-985.
130. Rossen J.D., Simonetti I., Marcus M.L., Winniford M.D. Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip. Circulation. 79:1989;566-572.
131. Parodi O., Neglia D., Palombo C., Sambuceti G., Giorgetti A., Marabotti C., Gallopin M., Simonetti I., L’Abbate A. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation. 96:1997;864-873.
132. Leenders K.L., Beaney R.P., Brooks D.J., Lammertsma A.A., Heather J.D., McKenzie C.G. Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology. 35:1985;1610-1616.
133. Sasajima T., Mineura K., Sasaki J., Kowada M., Tomura N., Hatazawa J., Ogawa T., Uemura K. Positron emission tomographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumor necrosis factor-alpha. J. Neurooncol. 23:1995;67-73.
134. Beanlands R.S., Bach D.S., Raylman R., Armstrong W.F., Wilson V., Montieth M., Moore C.K., Bates E., Schwaiger M. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 22:1993;1389-1398.
135. 11C-acetate and PET. Comar D. Developments in Nuclear Medicine: PET for Drug Development and Evaluation. 1995;253-262 Kluwer, Dordrecht.
136. 11C]3-O-methyl-D-glucose and positron emission tomography. J. Cereb. Blood Flow Metab. 6:1986;240-244.